Merus N.V. (MRUS) News
Filter MRUS News Items
MRUS News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
MRUS News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest MRUS News From Around the Web
Below are the latest news stories about MERUS NV that investors may wish to consider to help them evaluate MRUS as an investment opportunity.
Jim Cramer Says Merus (MRUS) Still ‘Very Speculative’We recently published a list of 10 Jim Cramer Stocks to Watch in 2025. In this article, we are going to take a look at where Merus N.V. (NASDAQ:MRUS) stands against other Jim Cramer stocks to watch in 2025. Jim Cramer in a latest program on CNBC commented on the bearish start of 2025 and […] |
Merus announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 3L+ mCRCUTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®) for cancer, today announced that the first patient has been dosed in the Company’s phase 2 trial evaluating petosemtamab monotherapy in heavily pretreated (3L+) metastatic colorectal cancer (mCRC). Petosemtamab is a Biclonics® targeting EGFR and LGR5. The phase 2, open |
Merus (MRUS): FDA Approval and Speculative Future in Cancer TherapyWe recently published a list of Jim Cramer’s Lightning Rounds: 12 Stocks Under the Spotlight. In this article, we are going to take a look at where Merus N.V. (NASDAQ:MRUS) stands against other stocks under Jim Cramer’s lightning rounds’ spotlight. Jim Cramer, host of Mad Money, recently discussed the outlook for the stock market following […] |
Merus’ Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCCPetosemtamab in combination with pembrolizumab in 1L r/m PD-L1 expressing HNSCC ongoing with clinical data update planned for 2025 Petosemtamab in mCRC evaluation expanded to include 1L and 3L+; initial clinical data planned for 2025 – Conference Call on Saturday, December 7th at 9:00 a.m. ET UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 07, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-len |
Merus Scores Its First FDA Approval For Lung Cancer DrugOn Wednesday, the FDA approved Merus N.V.’s (NASDAQ:MRUS) Bizengri (zenocutuzumab-zbco) as the first and only treatment indicated for adults with pancreatic adenocarcinoma or non–small cell lung cancer (NSCLC) that are advanced unresectable or metastatic and harbor a neuregulin 1 (NRG1) gene fusion who have disease progression on or after prior systemic therapy. Bizengri is Merus’s first approved medicine and is based on the proprietary Biclonics technology platform. Also Read: Merus Licenses US |
Merus’ Bizengri granted FDA accelerated approval to treat NRG1+ cancersThe FDA has granted accelerated approval to Bizengri in the treatment of advanced, unresectable NG1+ lung and pancreatic cancers. |
Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy StudyBIZENGRI® is the first and only therapy approved by the FDA specifically for pancreatic adenocarcinoma and NSCLC that harbor NRG1 gene fusions and are advanced unresectable or metastatic1Merus and Partner Therapeutics announced a license agreement for U.S. commercialization UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) [Merus, the Company, we, or our], a clinical-stage oncology company developing innovative, full-length, multispecific |
Merus price target lowered to $109 from $111 at GuggenheimGuggenheim lowered the firm’s price target on Merus (MRUS) to $109 from $111 and keeps a Buy rating on the shares after the company announced an exclusive agreement with privately-held Partner Therapeutics to exclusively licensed to PTx the right to commercialize zenocutuzumab for the treatment of NRG1 fusion-positive cancer in the U.S. The firm is updating its model to account for the license agreement, the analyst tells investors. Published first on TheFly – the ultimate source for real-time, |
Merus Licenses US Commercialization Rights For Cancer Potential Zenocutuzumab, Analyst Highlight Merus' PipelineMerus N.V. (NASDAQ:MRUS) and Partner Therapeutics Inc, a private biotechnology company focused on hematology and oncology, entered into an agreement in which Merus has exclusively licensed to Partner Therapeutics the right to commercialize zenocutuzumab (Zeno) for NRG1 fusion-positive (NRG1+) cancer in the U.S. Under the terms of the agreement, following a specified transition period, Partner Therapeutics will assume full rights to U.S. commercialization of Zeno for the treatment of NRG1+ cancer |
Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive CancerUTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®) and Partner Therapeutics, Inc. (PTx), a private, fully-integrated biotechnology company with a focus in hematology and oncology, today announced they have entered into an agreement in which Merus has exclusively licensed to PTx the righ |